Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

Six-year-olds. Novo’s new frontier for weight-loss drugs

Financial TimesView source article

Part of story

Novo Nordisk's Wegovy shows weight-loss benefit in children as young as six

Novo Nordisk released full Phase 3 trial results showing Wegovy lowered BMI and obesity rates in children aged 6 and older, though younger children who took the drug showed reduced growth rates.

Nov 16, 2026·3 sourcesClinical trialsDrug Policy, Pricing & ApprovalObesity treatmentNovo NordiskDrug safetyAdolescent healthGLP-1 drugsZepboundChildhood obesityWeight loss drugsEli Lilly
Novo Nordisk's Wegovy shows weight-loss benefit in children as young as six
00

Other sources for this story

CNBC

Novo says Wegovy injection lowers BMI and obesity rates in children in trial

The Wall Street Journal

Weight-Loss Drugs for Elementary-Age Children Succeed in Study